Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method.
1. A method of inducing the production of anti-HIV-1 antibodies in a subject comprising administering to the subject a composition comprising a liposome and a MPER656-GTH1 peptide (SEQ ID NO: 4) in an amount sufficient to effect said induction, wherein the peptide is embedded in the liposome via the GTH1 linker, and wherein the liposome comprises a viral membrane lipid or an anionic lipid.
2. The method of claim 1 , wherein the liposome comprises POPC (1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphocholine).
3. The method of claim 1 , wherein the liposome comprises cholesterol.
4. The method of claim 1 , wherein the liposome comprises POPC, POPE (1-Palmitoyl-2-Oleoyl-sn-Glycero-3-Phosphoethanolamine), DMPA (1,2-Dimyristoyl-sn-Glycero-3-Phosphate), and Cholesterol.
5. The method of claim 1 , wherein the liposome comprises POPC and 1-palmitoyl-2-oleoyl-sn-glycero-3-[phospho-L-serine] (POPS).
6. The method of claim 1 , wherein the liposome comprises POPC, POPS and lysophosphorylcholine (lysoPC).
7. The method of claim 1 , wherein the liposome comprises POPC, POPE, Sphingomyelin, and Cholesterol.
8. The method of claim 1 , wherein the liposome comprises DOPC and cholesterol.
9. The method of claim 1 , wherein the liposome comprises DPPC, DPPG, and cholesterol.
10. The method of claim 1 , wherein the composition further comprises alum.
11. The method of claim 1 , wherein the composition further comprises lipid A, oCpG, or TLR agonist.
12. The method of claim 1 , wherein the anionic lipid is phosphatidylserine.
13. The method of claim 1 , wherein the anionic lipid is phosphatidic acid.
14. The method of claim 1 , wherein the anionic lipid is cardiolipin.
15. The method of claim 1 , wherein the liposome comprises a sphingolipid.
16. The method of claim 1 , wherein the peptide embedded in the liposome binds an MPER neutralizing antibody.
17. The method of claim 1 , wherein peptide embedded in the liposome binds an MPER neutralizing antibody 2F5 or 4E10.
18. The method of claim 1 , wherein the composition further comprises an adjuvant.